Synpromics Ltd. has entered a research collaboration with GE Healthcare to jointly develop customized synthetic promoters optimized for GE Healthcare’s biopharmaceutical manufacturing platform.
 
Synpromics will develop a bar-coded library of synthetic promoters using its PromPT platform for extensive screening in GE’s Chinese Hamster Ovary (CHO) – based expression system. The resulting characterized promoter toolbox may have broad applicability for increasing the yield of a range of biopharmaceuticals, including difficult to manufacture proteins. Synpromics will receive an upfront technology access fee and will have the rights to commercialize the improved platform.
 
Dr. David Venables, chief executive officer of Synpromics, said, “We are delighted to be working with GE Healthcare, a world leading technology innovator to develop and commercialize our novel synthetic promoter platform. We believe our synthetic promoters will provide a much more efficient production system and we’re aiming to help GE Healthcare boost efficiency for its biopharma customers.”
 
“We are happy to be able to collaborate with Synpromics on developing enhanced tools for manufacturing biologics and thereby support our customers in their production efforts” said Morgan Norris, GM, Upstream and Cell Culture for GE Healthcare’s Life Sciences business.